CNS Drugs

Papers
(The TQCC of CNS Drugs is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Author’s Reply to Liu et al.: “A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal‑Onset Epilepsy”186
Comment on: “A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal‑Onset Epilepsy”134
Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs100
Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status“85
Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability84
Thrombolysis with Recombinant Human Prourokinase 4.5–6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial80
Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials75
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Non-Inferiority, Phase III Clinical Trial Evaluating the Efficacy and Safety of Emulsified Isoflurane for Anesthesia Induction in Patients74
Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use71
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem69
Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia67
Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis63
The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson’s Disease with Motor Fluctuatio57
The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis56
Daridorexant in Insomnia Disorder: A Profile of Its Use55
Correction to: Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life‑Sustaining Therapies: A Systematic Review55
Risdiplam: A Review in Spinal Muscular Atrophy55
Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav®) in Sleep Disorders: A Profile of Its Use51
The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study44
Pharmacotherapy for Frontotemporal Dementia44
The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies42
Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology42
Alternative Routes of Administration of Clozapine40
Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients40
Pharmacotherapy for Seizures in Tuberous Sclerosis Complex38
Apixaban for the Treatment of Cerebral Venous Sinus Thrombosis: A Single-Centre Experience and Systematic Review of the Literature38
Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies37
Idiopathic Hypersomnia: Neurobiology, Diagnosis, and Management37
Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis37
Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study37
Psychotropic Drugs Reemerging as Headache Medicines36
Over the Counter Supplements for Memory: A Review of Available Evidence34
Unmet Needs in Psychodermatology: A Narrative Review34
Third-Generation Antiseizure Medication in the Treatment of Benzodiazepine-Refractory Status Epilepticus in Poststroke Epilepsy: A Retrospective Observational Register-Based Study34
Observation on the Analgesic Effect of Different Doses of a Combination of Esketamine and Dexmedetomidine Administered for Percutaneous Endoscopic Transforaminal Discectomy: A Randomized, Double-Blind32
The Use of Ketamine for the Treatment of Anhedonia in Depression31
Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012–2021) from a University Hospital in Germany31
Correction: Efficacy of Cariprazine in the Psychosis Spectrum: A Systematic Review and Network Meta‑Analysis of Randomised Controlled Trials in Schizophrenia and Bipolar Disorder29
When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis29
Comparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-analysis of Congenital Malformations and Prenatal Outcomes29
Current Landscape of NTRK Inhibition for Pediatric CNS Tumors28
The State of Synthetic Cannabinoid Medications for the Treatment of Pain28
Correction to: Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 202228
Treatment with Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) and the Risk of All-Cause Poisoning in Children and Adolescents: A Self-Controlled Case Series Study27
Correction to: The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond27
The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Ran26
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies26
Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients’ Perspectives25
Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder24
Comment on “Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population”24
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease24
New and Emerging Drug and Gene Therapies for Friedreich Ataxia23
BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets23
Correction: Antiseizure Medications and Sudden Unexpected Death in Epilepsy: An Updated Review22
COMT Inhibitors in the Management of Parkinson’s Disease22
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?22
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies22
Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain22
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders21
FcRn Inhibitor Therapies in Neurologic Diseases21
Sodium Oxybate: Practical Considerations and Patient Perspectives21
Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis21
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies21
Update on Neuroprotection after Traumatic Brain Injury19
A Survey of People Living with Narcolepsy in the USA: Path to Diagnosis, Quality of Life, and Treatment Landscape from the Patient’s Perspective19
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study18
Authors’ Reply to Chevle et al.: Comment on “Erythropoietin Improves Poor Outcomes in Preterm Infants with Intraventricular Hemorrhage”17
Hypnotic and Melatonin/Melatonin-Receptor Agonist Treatment in Bipolar Disorder: A Systematic Review and Meta-Analysis17
Acknowledgement to Referees17
Comparative Effectiveness of Different Opioid Regimens, in Daily Dose or Treatment Duration, Prescribed at Surgical Discharge: a Systematic Review and Meta-Analysis17
Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis17
Disparities in Access to Reperfusion Therapy for Acute Ischemic Stroke (DARTS): A Comprehensive Meta-Analysis of Ethnicity, Socioeconomic Status, and Geographical Factors17
Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach16
Ketamine and Zinc: Treatment of Anorexia Nervosa Via Dual NMDA Receptor Modulation16
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis16
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders16
Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine16
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study16
Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy16
Treatment of Seizures in People with Intellectual Disability16
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial16
Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine15
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine N15
Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data14
Measuring Disease Progression in Multiple Sclerosis Clinical Drug Trials and Impact on Future Patient Care14
Effects of One-Year Anti-seizure Treatment with Add-On Cenobamate on Bone Density and Bone Turnover in Adults with Drug-Resistant Focal Epilepsy: An Observational Study14
Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review14
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controll14
Potential Role of Curcumin for the Treatment of Major Depressive Disorder14
Correction to: Effect of Enzyme‑Inducing Antiseizure Medications on the Risk of Sub‑Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study14
Safety and Efficacy of Ecopipam in Patients with Tourette Syndrome: A Systematic Review and Meta-analysis14
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder14
Irritability in Mood Disorders: Neurobiological Underpinnings and Implications for Pharmacological Intervention14
Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority Trial14
0.097831010818481